Skip to main content

2019 | OriginalPaper | Buchkapitel

Biomarker Enrichment Design Considerations in Oncology Single Arm Studies

verfasst von : Hong Tian, Kevin Liu

Erschienen in: Pharmaceutical Statistics

Verlag: Springer International Publishing

Aktivieren Sie unsere intelligente Suche um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Oncology drug development has been increasingly shaped by molecularly targeted agents (MTAs), which often demonstrate differential effectiveness driven by the biomarker expression levels on tumors. Innovative statistical designs have been proposed to tackle this challenge, e.g., Freidlin et al. [3, 4], Jiang et al. [7]. All of these are essentially adaptive confirmatory Phase 3 designs that combine the testing of treatment effectiveness in the overall population with an alternative pathway for a more restrictive efficacy claim in a sensitive subpopulation. We believe that, in cases that there are strong biological rationales to support that a MTA may provide differential benefit in a general patient population; proof-of-concept (POC) is likely intertwined with predictive enrichment. Therefore, it is imperative that early phase POC studies be designed to specifically address biomarker-related questions to improve the efficiency of development. In this paper, we propose three strategies for detecting efficacy signals in single-arm studies that allow claiming statistical significance either in the overall population or in a biomarker enriched subpopulation. None of the three methods requires pre-specification of biomarker thresholds, but still maintains statistical rigor in the presence of multiplicity. The performance of these proposed methods are evaluated with simulation studies.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literatur
1.
Zurück zum Zitat Alosh, M., Huque, M.F.: A flexible strategy for testing subgroups and overall population. Stat. Med. 28, 3–23 (2009)MathSciNetCrossRef Alosh, M., Huque, M.F.: A flexible strategy for testing subgroups and overall population. Stat. Med. 28, 3–23 (2009)MathSciNetCrossRef
2.
Zurück zum Zitat Alosh, M., Huque, M.F.: A consistency-adjusted alpha-adaptive strategy for sequential testing. Stat. Med. 29, 1559–1571 (2010)MathSciNet Alosh, M., Huque, M.F.: A consistency-adjusted alpha-adaptive strategy for sequential testing. Stat. Med. 29, 1559–1571 (2010)MathSciNet
3.
Zurück zum Zitat Freidlin, B., Simon, R.: Adaptive signature design: an adaptive clinical trial design for generating 1519 and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer 1520 Res. 11, 7872–7878 (2005)CrossRef Freidlin, B., Simon, R.: Adaptive signature design: an adaptive clinical trial design for generating 1519 and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer 1520 Res. 11, 7872–7878 (2005)CrossRef
4.
Zurück zum Zitat Freidlin, B, Jiang, W., Simon, R.: The cross-validated adaptive signature design. Clin. Cancer 1522 Res. 16, 691–698 (2010)CrossRef Freidlin, B, Jiang, W., Simon, R.: The cross-validated adaptive signature design. Clin. Cancer 1522 Res. 16, 691–698 (2010)CrossRef
5.
Zurück zum Zitat Food and Drug Administration. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, 25 May 2005 Food and Drug Administration. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, 25 May 2005
6.
7.
Zurück zum Zitat Jiang, W., Freidlin, B., Simon, R.: Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl. Cancer Inst. 99(13), 1036–1043 (2007)CrossRef Jiang, W., Freidlin, B., Simon, R.: Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl. Cancer Inst. 99(13), 1036–1043 (2007)CrossRef
8.
Zurück zum Zitat Lyles, R., Lin, J.: Sensitivity analysis for misclassification in logistic regression via likelihood methods and predictive value weighting. Stat. Med. 29(22), 2297–2309 (2010)MathSciNetCrossRef Lyles, R., Lin, J.: Sensitivity analysis for misclassification in logistic regression via likelihood methods and predictive value weighting. Stat. Med. 29(22), 2297–2309 (2010)MathSciNetCrossRef
9.
Zurück zum Zitat Song, Y., Chi, G.Y.: A method for testing a prespecified subgroup in clinical trials. Stat. Med. 26, 3535–3549 (2007)MathSciNetCrossRef Song, Y., Chi, G.Y.: A method for testing a prespecified subgroup in clinical trials. Stat. Med. 26, 3535–3549 (2007)MathSciNetCrossRef
Metadaten
Titel
Biomarker Enrichment Design Considerations in Oncology Single Arm Studies
verfasst von
Hong Tian
Kevin Liu
Copyright-Jahr
2019
DOI
https://doi.org/10.1007/978-3-319-67386-8_15